PharmaEssentia – Applying the Power of Interferon to Treat Cancers Differently

Meredith Manning, President of the Americas at PharmaEssentia, a global biotech, discusses the company’s work utilizing the power of interferons, a naturally occurring substance that helps the body’s immune system fight infection and diseases. PharmaEssentia has pioneered technology that leverages pegylation (or “extended release”) to administer interferons in a tolerable and effective way to treat certain myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) at the source. This has opened the door to applying this therapy to other forms of rare blood cancers. Meredith discusses the importance of educating patients and physicians on early intervention to reduce the risk of disease progression. Meredith is passionate about solving the most pressing challenges in MPNs and is focused on cultivating relationships with community physicians to help more patients.

Meredith joined PharmaEssentia as General Manager for the U.S. in 2020, bringing with her more than 20 years of experience in global commercialization and brand building for biopharmaceuticals and medical devices. She was most recently Chief Commercial Officer at resTORbio™, and previously served as Vice President of Global Product Strategy in Hemophilia for Shire (formerly Baxalta) and Baxter. She previously held a series of marketing leadership roles at Vertex ® and Pfizer.

Meredith received a BS at Colorado College and an MBA from the University of Chicago Booth School of Business.